Portal de investigação
Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Cleland, JGF
- Girerd, N
- Pellicori, P
- Hazebroek, MR
- Verdonschot, J
- Collier, TJ
- Petutschnigg, J
- Clark, AL
- Staessen, JA
- Heymans, S
- Zannad, F
- Rossignol, P
Unidades de investigação
Abstract
[No abstract available]
Dados da publicação
- ISSN/ISSNe:
- 1861-0692, 1861-0684
- Tipo:
- Letter
- Páginas:
- 330-332
- Link para outro recurso:
- www.scopus.com
Clinical Research in Cardiology D. Steinkopff-Verlag
Citações Recebidas na Web of Science: 2
Citações Recebidas na Scopus: 5
Documentos
- Não há documentos
Filiações
Keywords
- Heart Failure; Humans; Kidney; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Treatment Outcome; brain natriuretic peptide; hepatitis A virus cellular receptor 1; loop diuretic agent; natriuretic factor; potassium; renin; spironolactone; mineralocorticoid antagonist; spironolactone; atrial fibrillation; blood pressure; clinical trial (topic); collagen synthesis; controlled study; coronary artery disease; diabetes mellitus; ECG abnormality; estimated glomerular filtration rate; heart failure; heart function; heart left ventricle ejection fraction; human; hypertension; kidney function; Letter; microalbuminuria; randomized controlled trial (topic); risk factor; systolic blood pressure; heart failure; heart stroke volume; kidney; physiology; treatment outcome
Financiamento
Proyectos asociados
Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684
Investigador Principal: João Pedro Melo Marques Pinho Ferreira
Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022
Citar a publicação
Ferreira JP,Cleland JGF,Girerd N,Pellicori P,Hazebroek MR,Verdonschot J,Collier TJ,Petutschnigg J,Clark AL,Staessen JA,Heymans S,Zannad F,Rossignol P. Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial. Clin. Res. Cardiol. 2023. 112(2):p. 330-332. IF:5,000. (2).
